Találati lista | Tudóstér

001-es BibID:	BIBFORM019953
Első szerző:	Lakatos Péter (Semmelweis Egyetem)
Cím:	Serum lipopolysaccharide-binding protein and soluble CD14 are markers of disease activity in patients with Crohn's disease / Lakatos P. L., Kiss L. S., Palatka K., Altorjay I., Antal-Szalmas P., Palyu E., Udvardy M., Molnar T., Farkas K., Veres G., Harsfalvi J., Papp J., Papp M.
Dátum:	2011
Megjegyzések:	In inflammatory bowel disease (IBD), enhanced inflammatory activity in the gut is thought to increase the risk of bacterial translocation and endotoxemia. In the present study we investigated the association between serum level of lipopolysaccharide-binding protein (LBP), soluble CD14 (sCD14), and clinical disease activity, high-sensitivity C-reactive protein (hs-CRP), antimicrobial serology profile, NOD2/CARD15 status, and clinical phenotype in a large cohort of Hungarian Crohn's disease (CD) patients. METHODS: In all, 214 well-characterized, unrelated, consecutive CD patients (male/female ratio: 95/119; age: 35.6 ± 13.1 years; duration:8.3 ± 7.5 years) and 110 healthy controls were investigated. Sera were assayed for LBP, sCD14, hs-CRP, ASCA IgG/IgA, anti-OMP IgA, and pANCA antibodies. NOD2/CARD15 and TLR4 variants were tested. Detailed clinical phenotypes were determined by reviewing the patients' medical charts. RESULTS: Serum LBP level was significantly higher (P < 0.0001 for both), while sCD14 was lower (P < 0.0001) in both active and inactive CD compared to the controls. The accuracy of hs-CRP (area under the curve [AUC] = 0.66), sCD14 (AUC = 0.70), and LBP (AUC = 0.58) was comparable for identifying patients with active disease. There was a significant correlation between LBP (P < 0.001), sCD14 (P = 0.015), and hs-CRP levels but not with antimicrobial seroreactivity or NOD2/CARD15 genotype. In inactive CD, LBP was associated with penetrating disease. In a Kaplan-Meier analysis and a proportional Cox-regression analysis, LBP (P = 0.006), sCD14 (P = 0.007), and previous relapse frequency (P = 0.023) were independently associated with time to clinical relapse during a 12-month follow-up period. CONCLUSIONS: Serum LBP and sCD14 are markers of disease activity in CD with a similar accuracy as hs-CRP. In addition, LBP, sCD14, and a high frequency of previous relapses were independent predictors for 1-year clinical flare-up. (Inflamm Bowel Dis 2011).
Tárgyszavak:	Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban egyetemen (Magyarországon) készült közlemény
Megjelenés:	Inflammatory Bowel Disease. - 17 : 3 (2011), p. 767-777. -
További szerzők:	Kiss Lajos Sándor Palatka Károly (1961-) (belgyógyász, gasztroenterológus) Altorjay István (1954-) (belgyógyász, gasztroenterológus, onkológus) Antal-Szalmás Péter (1968-) (laboratóriumi szakorvos) Pályu Eszter (1983-) Udvardy Miklós (1947-) (belgyógyász, haematológus) Molnár Tamás (orvos Szeged) Farkas Klaudia Veres Gábor (1969-2020) (csecsemő- és gyermekgyógyász, gasztroenterológus) Hársfalvi Jolán (1949-) (klinikai biokémikus) Papp János (Budapest) Papp Mária (1975-) (belgyógyász, gasztroenterológus)
Internet cím:	Intézményi repozitóriumban (DEA) tárolt változat DOI
Borító:
Saját polcon:

001-es BibID:	BIBFORM075566
Első szerző:	Nagy Gábor (laboratóriumi szakorvos, laboratóriumi hematológus és immunológus)
Cím:	Monitoring of drug level and anti-drug antibody production during vedolizumab therapy in patients with inflammatory bowel disease / G. Nagy, É. Török, K. Palatka, Z. Kébel, P. Antal-Szalmás
Dátum:	2018
Megjegyzések:	Integrin ?4?7 is expressed on gut-specific lymphocytes and plays a pivotal role in their migration to the intestine. Vedolizumab (VDZ, trade name Entyvio), a humanized monoclonal IgG1 antibody to the ?4?7 integrin blocks their adhesion to the gut vascular endothelium. In 2014 Entyvio was approved for patients with ulcerative colitis (UC) and Crohn's disease (CD) in Hungary. Our aim was to find and evaluate laboratory tests capable of measuring vedolizumab and anti-vedolizumab antibody (AVA) levels. After overviewing the available methods, LISA-TRACKER Duo Vedolizumab ELISA kit (ref: LTV 005, TheraDiag, Croissy-Beaubourg, France) was chosen. Seventeen samples of 15 patients (9 UC/6 CD) were analyzed. Mean VDZ levels were 18.2 ?g/mL and 7.4 ?g/mL in patients with UC and CD, respectively (p=0.242). Drug levels were significantly higher in patients on concomitant immune modulating therapy (16.9 ?g/mL vs 3.9 ?g/mL, p=0.033). There was no significant correlation between drug concentrations and CRP or disease activity scores. Anti-vedolizumab antibody was not detected in any of the patients (0/15) in accordance with the approximately 4% AVA positivity reported in vedolizumab immunogenicity studies (p=0.430). Five patients had drug levels under the measuring range of the test (<2 ?g/mL) suggesting the possibility of having low affinity anti-drug antibodies not detected by the bridging ELISA method used. In conclusion, LISA-TRACKER Duo Vedolizumab ELISA kit seems to be appropriate to monitor drug and anti-drug antibody levels in patients with inflammatory bowel disease. However, insensitivity of the ELISA methods for detecting low affinity anti-drug antibody may limit its use to determine immunogenicity of vedolizumab.
Tárgyszavak:	Orvostudományok Klinikai orvostudományok idézhető absztrakt
Megjelenés:	Clinical Chemistry and Laboratory Medicine. - 56 : 9 (2018), p. eA162. -
További szerzők:	Török Éva Palatka Károly (1961-) (belgyógyász, gasztroenterológus) Kébel Z. Antal-Szalmás Péter (1968-) (laboratóriumi szakorvos)
Internet cím:	Szerző által megadott URL DOI Intézményi repozitóriumban (DEA) tárolt változat
Borító:
Saját polcon:

001-es BibID:	BIBFORM056494
Első szerző:	Tanyi Miklós (sebész)
Cím:	MLH1 and MSH2 mutation screening in HNPCC families of Hungary - Two new MMR gene mutations / M. Tanyi, J. Olasz, J. L. Tanyi, L. Tóth, P. Antal-Szalmás, Z. Ress, T. Bubán, K. Palatka, C. András, H. Urbancsek, Z. Garami, O. Csuka, L. Damjanovich
Dátum:	2014
Megjegyzések:	Hereditary Non-Polyposis Colorectal Cancer is an inherited disease with deleterious germline mutations in the DNA mismatch repair genes causing the development of colon cancer and other malignancies. This is the first study in Hungary screening the population of our colorectal cancer patients in order to identify the prevalence of the disease. METHODS: In families who met the Modified Amsterdam and Bethesda Criteria the removed tumor tissue was first examined by immunohistochemistry and microsatellite instability analysis. Those cases which showed high microsatellite instability underwent DNA sequencing and multiple ligation dependent probe amplification. RESULTS: Of the 1576 patients with colorectal cancer underwent screening for the modified Amsterdam and Bethesda criteria, 69 (4.4%) and 166 (10.5%) fulfilled the criteria respectively. 15 patients (31%) of the Amsterdam positive group and 19 patients from the Bethesda positive (18.1%) were MSI-H. There were 8 pathogenic mutations identified in 9 families (60%) in the Amsterdam positive group. 5 mutations were found in 5 families (26%) in the Bethesda positive group. 12 pathogenic mutations were identified, two of these are newly identified, and being published first in this work. These two new mutations were located on MLH1 (g.31276_35231del) and MSH2 (c.969_970delTC) genes. CONCLUSION: The prevalence of the mutations in the MLH1 and MSH2 genes was almost equal in our Hungarian colorectal cancer patients. One mutation in the MLH1 gene (c.143A > C; p.Q48P) was identified in three different families. Whether this mutation is the most frequent in the Hungarian population is still unidentified and warrant further investigation.
Tárgyszavak:	Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
Megjelenés:	European Journal of Surgical Oncology . - 40 : 11 (2014), p. 1445-1452. -
További szerzők:	Olasz J. (Budapest) Tanyi János L. Tóth László (1971-) (patológus) Antal-Szalmás Péter (1968-) (laboratóriumi szakorvos) Ress Zsuzsa (1976-) (belgyógyász) Bubán Tamás (1967-) (belgyógyász, gasztroenterológus) Palatka Károly (1961-) (belgyógyász, gasztroenterológus) András Csilla (1961-) (onkológus szakorvos) Urbancsek Hilda (1966-) Garami Zoltán (1963-) (orvos) Csuka Orsolya Damjanovich László (1960-) (általános sebész)
Internet cím:	Intézményi repozitóriumban (DEA) tárolt változat
Borító:
Saját polcon: